Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Quetiapine and essential tremor.

Federico Micheli1, María Graciela Cersósimo, Gabriela Raina

  • 1Parkinson's Disease and Abnormal Movements Program, Institute of Neurosciences, José de San Martin Hospital de Clínicas, Buenos Aires, Argentina. Fmicheli@fibertel.com.ar

Clinical Neuropharmacology
|December 7, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Essential genetic testing in movement disorders - results from a Delphi study.

Parkinsonism & related disorders·2026
Same author

Probiotic, Prebiotic, or Synbiotic Supplementation in Parkinson's Disease: A Systematic Review and Meta-Analysis with Trial Sequential Analysis.

Gerontology·2026
Same author

Public Health.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

How Do I Diagnose Multiple System Atrophy-A Videolibrary on Clinical and Imaging Features.

Movement disorders clinical practice·2025
Same author

Sex differences in the diagnosis latency of Parkinson's disease in Latin America.

Parkinsonism & related disorders·2025
Same author

Diagnostic MRI Score to Differentiate Susac Syndrome from Primary Angiitis of the Central Nervous System and Multiple Sclerosis.

Annals of neurology·2024

Quetiapine monotherapy for essential tremor showed a good safety profile in a small trial. While not definitively effective, some patients experienced benefits, suggesting potential for future research.

Area of Science:

  • Neurology
  • Clinical Pharmacology

Background:

  • Essential tremor (ET) is a common neurological disorder.
  • Current treatments for ET have limitations and side effects.
  • Quetiapine is an atypical antipsychotic with potential off-label uses.

Purpose of the Study:

  • To investigate the safety and tolerability of quetiapine as monotherapy for essential tremor.
  • To explore preliminary efficacy signals of quetiapine in ET patients.

Main Methods:

  • Open-label study involving 10 patients with essential tremor.
  • Dose escalation of quetiapine up to 75 mg/day over 6 weeks.
  • Monitoring for adverse events and assessing tremor improvement.

Main Results:

Related Experiment Videos

  • Quetiapine was generally safe and tolerable in this small cohort.
  • Adverse events included paradoxical psychiatric reactions and somnolence, leading to discontinuation or dose reduction in some patients.
  • No significant pre- versus post-treatment differences were observed, but 30% of patients showed >20% improvement.

    • Conclusions:

    • Quetiapine appears to be a safe option for essential tremor treatment.
    • Further powered studies are needed to confirm efficacy and optimal dosing for ET.